Wahed Invest LLC Biomarin Pharmaceutical Inc Transaction History

Wahed Invest LLC

$555 Million
Q3 2024

A detailed history of Wahed Invest LLC transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Wahed Invest LLC holds 4,584 shares of BMRN stock, worth $297,960. This represents 0.06% of its overall portfolio holdings.

Number of Shares

4,584

Previous 4,114 11.42%

Holding current value

$297,960

Previous $338,000 4.73%

% of portfolio

0.06%

Previous 0.07%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$69.02 - $93.84 $32,439 - $44,104	470 Added 11.42%	4,584 $322,000
Q2 2024 Aug 14, 2024	BUY	$74.43 - $92.22 $34,237 - $42,421	460 Added 12.59%	4,114 $338,000
Q1 2024 May 15, 2024	BUY	$83.81 - $99.0 $38,804 - $45,837	463 Added 14.51%	3,654 $319,000
Q4 2023 Mar 11, 2024	SELL	$76.22 - $98.51 $100,229 - $129,540	-1,315 Reduced 29.18%	3,191 $307,000
Q4 2023 Feb 14, 2024	BUY	$76.22 - $98.51 $122,333 - $158,108	1,605 Added 55.33%	4,506 $434,000
Q3 2023 Nov 14, 2023	BUY	$85.07 - $94.48 $17,609 - $19,557	207 Added 7.68%	2,901 $256,000
Q2 2023 Aug 14, 2023	BUY	$86.68 - $100.3 $24,183 - $27,983	279 Added 11.55%	2,694 $233,000
Q1 2023 May 15, 2023	BUY	$87.74 - $117.27 $5,439 - $7,270	62 Added 2.63%	2,415 $234,000
Q4 2022 Feb 14, 2023	BUY	$80.93 - $108.63 $18,937 - $25,419	234 Added 11.04%	2,353 $243,000
Q3 2022 Nov 14, 2022	BUY	$82.16 - $96.94 $11,995 - $14,153	146 Added 7.4%	2,119 $180,000
Q2 2022 Aug 15, 2022	BUY	$71.48 - $86.85 $141,030 - $171,355	1,973 New	1,973 $164,000
Q1 2022 May 16, 2022	SELL	$74.28 - $92.69 $162,153 - $202,342	-2,183 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$71.72 - $91.47 $156,564 - $199,679	2,183 New	2,183 $193,000

Others Institutions Holding BMRN

# of Institutions

637

Shares Held

177M

Call Options Held

2.01M

Put Options Held

1.28M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wahed Invest LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wahed Invest LLC with notifications on news.

Account